EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma

Christopher L Moertel iD, Angela C Hirbe iD, Hans H Shuhaiber, Kevin Bielamowicz, Alpa Sidhu, David Viskochil, Michael D Weber, Armend Lokku, L Mary Smith, Nicholas K Foreman iD, Fouad M Hajjar, Rene Y McNall-Knapp und 30 weitere

Journal of Clinical Oncology · 20.02.2025 · 43 (6) · 716-729

DOI: 10.1200/jco.24.01034 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2025. Verfasst von Christopher L Moertel und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Minnesota, Minneapolis, MN. Hauptthemen laut MEDLINE: Neurofibroma, Plexiform, Neurofibromatosis 1, Benzamides, Antineoplastic Agents. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Pharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration–approved for adults. METHODS ReNeu is an open-label, multicenter, pivotal, phase IIb trial of mirdametinib in 58 adults (≥18 years of age) and 56 children (2 to 17 years of age) with NF1-PN causing significant morbidities. Patients received mirdametinib capsules or tablets for oral suspension (2 mg/m 2 twice daily, maximum 4 mg twice daily), regardless of food intake, in 3 weeks on/1 week off 28-day cycles. The primary end point was confirmed objective response rate (ORR; proportion of patients with a ≥20% reduction of target PN volume from baseline on consecutive scans during the 24-cycle treatment phase) assessed by blinded independent central review (BICR) of volumetric magnetic resonance imaging. RESULTS Twenty-four of 58 adults (41%) and 29 of 56 children (52%) had a BICR-confirmed objective response during the 24-cycle treatment phase; in addition, two adults and one child had confirmed responses during long-term follow-up. Median (range) target PN volumetric best response was –41% (−90 to 13) in adults and –42% (−91 to 48) in children. Both cohorts reported significant and clinically meaningful improvement in patient- or parent proxy-reported outcome measures of worst tumor pain severity, pain interference, and health-related quality of life (HRQOL) that began early and were sustained during treatment. The most commonly reported treatment-related adverse events were dermatitis acneiform, diarrhea, and nausea in adults and dermatitis acneiform, diarrhea, and paronychia in children. CONCLUSION In ReNeu, the largest multicenter NF1-PN trial reported to date, mirdametinib treatment demonstrated significant confirmed ORRs by BICR, deep and durable PN volume reductions, and early, sustained, and clinically meaningful improvement in pain and HRQOL. Mirdametinib was well-tolerated in adults and children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibroma, PlexiformNeurofibromatosis 1BenzamidesAntineoplastic AgentsHumansChildAdolescentMaleAdultFemaleChild, PreschoolMiddle AgedYoung AdultQuality of LifeAgedMagnetic Resonance Imaging

Substanzen

BenzamidesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pediatrics, University of Minnesota, Minneapolis, MN.
  • Washington University School of Medicine in St Louis, St Louis, MO.
  • University of Florida Clinical Research Center, Gainesville, FL.
  • The University of Arkansas for Medical Sciences/Arkansas Children's Hospital, Little Rock, AR.
  • University of Iowa Hospitals and Clinics, Iowa City, IA.
  • University of Utah, Salt Lake City, UT.

ORCID-Profile: Christopher L Moertel, Angela C Hirbe, Nicholas K Foreman, Andrea T Franson, Julia Meade, David Schiff, Tobias Walbert, Laura J Klesse, Paul L Moots, Miriam Bornhorst, Ana Aguilar-Bonilla, Punita Gupta, Laura K Metrock, P Leia Nghiemphu, Ryan D Roberts, Timothy R Gershon

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Moertel, C. L., Hirbe, A. C., Shuhaiber, H. H., Bielamowicz, K., Sidhu, A., Viskochil, D., Weber, M. D., Lokku, A., Smith, L. M., Foreman, N. K., Hajjar, F. M., McNall-Knapp, R. Y., Weintraub, L., Antony, R., Franson, A. T., Meade, J., Schiff, D., Walbert, T., Ambady, P., …, & ReNeu Study Investigators (2025). ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma. Journal of Clinical Oncology, 43(6), 716-729. https://doi.org/10.1200/jco.24.01034

Vancouver

Moertel CL, Hirbe AC, Shuhaiber HH, Bielamowicz K, Sidhu A, Viskochil D, et al. ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma. Journal of Clinical Oncology. 2025;43(6):716-729. doi:10.1200/jco.24.01034

BibTeX
@article{Moertel2025,
  author = {Moertel, Christopher L and Hirbe, Angela C and Shuhaiber, Hans H and Bielamowicz, Kevin and Sidhu, Alpa and Viskochil, David and Weber, Michael D and Lokku, Armend and Smith, L Mary and Foreman, Nicholas K and Hajjar, Fouad M and McNall-Knapp, Rene Y and Weintraub, Lauren and Antony, Reuben and Franson, Andrea T and Meade, Julia and Schiff, David and Walbert, Tobias and Ambady, Prakash and Bota, Daniela A and Campen, Cynthia J and Kaur, Gurcharanjeet and Klesse, Laura J and Maraka, Stefania and Moots, Paul L and Nevel, Kathryn and Bornhorst, Miriam and Aguilar-Bonilla, Ana and Chagnon, Sarah and Dalvi, Nagma and Gupta, Punita and Khatib, Ziad and Metrock, Laura K and Nghiemphu, P Leia and Roberts, Ryan D and Robison, Nathan J and Sadighi, Zsila and Stapleton, Stacie and Babovic-Vuksanovic, Dusica and Gershon, Timothy R and ReNeu Trial Investigators, ReNeu Trial Investigators and ReNeu Study Investigators, ReNeu Study Investigators},
  title = {ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {6},
  pages = {716--729},
  doi = {10.1200/jco.24.01034}
}
Kostenlos starten →